Medical Research Agency announced the results of the call for non-commercial clinical trials in psychiatry and neurology. We are pleased to announce that Medical University of Lodz is a leader for 2 projects accepted for financial support. Our Team in cooperation with Clinical Trials Unit Medical University of Lodz is involved will safeguard their successful realization.
One of the projects – “LAMAinDiab – lisdexamphetamine vs methylphenidate for paediatric patients with ADHD and type 1 diabetes – a randomized crossover clinical trial” – will be lead by our new Team member – assoc. prof. Agnieszka Butwicka! Congratulations!
The intervention within the “LAMAinDiab” aims at improving the control of ADHD symptoms in patients with type 1 diabetes. The project is conducted in cooperation between 4 pediatric diabetes centers in Poland (located in Łódź, Gdańsk, Katowice and Opole). The initiated therapy with lisdexamfetamine or methylphenidate, preceded by psychotherapeutic and educational intervention will translate into improvement to patients’ health status both with regard to control of ADHD symptoms and control of metabolism in diabetes. We hope that the trial results will provide valuable insight into recommended mode of treatment of this special group of patients.
Read more about our Projects here:
https://en.umed.pl/pln-20-mln-for-mul-non-commercial-clinical-trial-in-psychiatry-and-neurology/